Reclast (Zoledronic Acid) Cost in Minnesota: 2026 Pricing, Insurance, and Savings Guide

What Does Reclast (Zoledronic Acid) Actually Cost in Minnesota in 2026?

The price you pay for a zoledronic acid infusion in Minnesota depends on whether you use brand Reclast, a generic formulation, or a 503A compounded product, and whether insurance covers the drug, the infusion service, or both. Novartis lists brand Reclast at roughly $1,500 per infusion. Minnesota retail pharmacies report an average cash-pay price near $600 for generic zoledronic acid 5 mg/100 mL in 2026.

That headline number can mislead, though. Zoledronic acid is administered as a single intravenous infusion once per year for postmenopausal osteoporosis [1]. The drug cost is only one component. You also face a facility or infusion-center fee (often $150 to $400 for an outpatient visit) and a possible administration charge billed under CPT code 96365 for the first hour of IV infusion. A 2022 analysis in the Journal of Managed Care & Specialty Pharmacy found that total per-infusion costs for IV bisphosphonates in outpatient settings ranged from $800 to $2,200 depending on payer and site of care [2]. In rural Minnesota counties, infusion center access may be limited, which can push patients toward hospital outpatient departments where facility fees run higher.

Generic zoledronic acid has been available since 2013, when multiple manufacturers received FDA approval for 5 mg/100 mL IV solution [3]. Generic pricing typically runs 40% to 70% below brand Reclast. At a Minnesota retail pharmacy, expect $350 to $700 for the drug alone before any insurance or discount program is applied.

One important distinction: the $600 average cash price reflects the drug acquisition cost, not the total cost of the infusion visit. Always ask your infusion center for an all-inclusive estimate before scheduling.

Minnesota Medicaid Coverage for Zoledronic Acid

Minnesota Medical Assistance (the state Medicaid program) covers zoledronic acid for osteoporosis treatment, but requires prior authorization before the infusion is approved. The PA process confirms that the prescriber has documented a qualifying diagnosis, typically a T-score of -2.5 or lower on dual-energy X-ray absorptiometry (DXA), or a history of fragility fracture [4].

The Minnesota Department of Human Services formulary classifies IV bisphosphonates as "covered with conditions." Your prescribing clinician submits a PA request that includes DXA results, fracture history, and documentation that oral bisphosphonates were either tried, not tolerated, or contraindicated. Common reasons for oral bisphosphonate failure include esophageal disorders, inability to remain upright for 30 minutes after dosing, or documented poor adherence. The American Association of Clinical Endocrinology (AACE) 2020 guidelines specifically recommend IV zoledronic acid for patients who cannot take oral bisphosphonates [5].

PA turnaround in Minnesota Medicaid typically takes 3 to 5 business days. If denied, you have the right to appeal. Medicaid recipients pay $0 in co-pay for the drug itself once PA is granted, though facility fees at non-Medicaid-contracted infusion sites could create unexpected bills. Confirm that both the prescriber and the infusion facility accept Minnesota Medical Assistance before scheduling.

MinnesotaCare, the state's subsidized insurance program for residents who earn too much for Medicaid but too little for marketplace plans, also covers injectable osteoporosis treatments with similar PA requirements.

Insurance Coverage: Commercial Plans and Medicare in Minnesota

Most commercial insurance plans sold in Minnesota, including those offered through MNsure (the state health insurance marketplace), cover zoledronic acid for FDA-approved indications. Coverage sits under the medical benefit rather than the pharmacy benefit because the drug is physician-administered [6].

This classification matters for your wallet. Under medical benefit coverage, you pay a percentage coinsurance (commonly 20% after deductible) rather than a flat co-pay. For a $600 generic zoledronic acid infusion plus a $300 facility fee, a patient with 20% coinsurance after a met deductible would owe roughly $180. If your annual deductible has not been met, you could owe the full negotiated rate.

Medicare Part B covers zoledronic acid infusion at 80% of the Medicare-approved amount after the Part B deductible ($257 in 2026). A Medigap supplemental plan can pick up the remaining 20%. Medicare Advantage plans in Minnesota, offered by carriers such as UnitedHealthcare, Blue Cross Blue Shield of Minnesota, HealthPartners, and Medica, also cover zoledronic acid but may require step therapy or PA showing oral bisphosphonate intolerance.

"Zoledronic acid represents one of the most cost-effective osteoporosis interventions over a 3-year horizon because a single annual infusion replaces 365 days of oral pill burden," noted a 2019 cost-effectiveness analysis published in Osteoporosis International [7].

For patients with high-deductible health plans (HDHPs), the once-yearly dosing of zoledronic acid means the entire drug and infusion cost hits in a single claim. If you schedule your infusion early in the plan year, it can count toward your deductible and lower your out-of-pocket costs for the rest of the year.

Generic Zoledronic Acid vs. Brand Reclast: Price Comparison

Brand Reclast from Novartis carries a wholesale acquisition cost (WAC) near $1,500 per 5 mg infusion. Generic zoledronic acid 5 mg/100 mL, manufactured by companies including Mylan, Teva, Fresenius Kabi, and Hospira, typically costs $300 to $700 at Minnesota pharmacies and infusion centers.

The clinical evidence supports therapeutic equivalence. The FDA requires generic zoledronic acid to meet identical standards for active ingredient, strength, dosage form, and route of administration [3]. A 2018 retrospective cohort study of 12,480 patients switching from brand to generic IV bisphosphonates found no statistically significant difference in fracture rates at 24 months (HR 0.97 to 95% CI 0.88 to 1.07) [8].

Requesting generic zoledronic acid is the single most effective way to reduce your cost. Ask your prescriber to write "zoledronic acid 5 mg/100 mL IV" without specifying the Reclast brand. Most infusion centers stock generic formulations by default.

Price variability across Minnesota is real. The Mayo Clinic system in Rochester, Allina Health in the Twin Cities metro, and Essentia Health in Duluth each negotiate different acquisition costs from wholesalers. Calling two or three infusion sites to compare all-inclusive pricing can save $200 or more per infusion.

Compounded Zoledronic Acid in Minnesota: Legality and Access

Compounded zoledronic acid is available in Minnesota through licensed 503A compounding pharmacies. Under the Federal Food, Drug, and Cosmetic Act section 503A, a pharmacy may compound a drug for an individual patient with a valid prescription when a specific clinical need exists, such as an allergy to an inactive ingredient in the commercial product [9].

The Minnesota Board of Pharmacy regulates 503A pharmacies operating within the state. These pharmacies must comply with United States Pharmacopeia (USP) chapter 797 standards for sterile compounding, which is particularly relevant for an intravenous product like zoledronic acid. A compounded zoledronic acid preparation must be prepared in an ISO Class 5 cleanroom environment with proper beyond-use dating.

Compounded zoledronic acid can cost significantly less than commercial generic versions. Some 503A pharmacies quote prices in the range of $100 to $250 for a 5 mg dose. The trade-off is that compounded drugs are not FDA-approved and do not undergo the same batch-level testing and stability studies as commercial products.

Not every patient is a candidate. The FDA's position, reiterated in guidance updated in 2024, is that 503A compounding should not be used to create copies of commercially available drugs unless the prescriber documents a patient-specific clinical reason [10]. An inactive-ingredient allergy or a need for a non-standard concentration would qualify. Cost alone does not meet the FDA's threshold for patient-specific compounding.

Ask your prescriber whether a compounded formulation is appropriate for your situation before pursuing this route.

How to Save on Zoledronic Acid in Minnesota

Several discount pathways exist for Minnesota residents paying out of pocket or facing high coinsurance.

Novartis patient assistance and co-pay programs. Novartis offers a co-pay savings card for commercially insured patients receiving Reclast. Eligible patients may pay as little as $0 per infusion, with the program covering up to a specified annual maximum. Medicare and Medicaid beneficiaries are not eligible for co-pay cards due to federal anti-kickback rules. The Novartis Patient Assistance Foundation provides free drug to uninsured or underinsured patients who meet income thresholds (typically <400% of the federal poverty level) [11].

GoodRx and discount aggregators. Searching GoodRx, RxSaver, or SingleCare for "zoledronic acid 5 mg/100 mL" at Minnesota zip codes can surface cash prices $100 to $200 below the pharmacy's standard retail rate. These coupons apply to the drug cost only, not the infusion service fee.

Hospital financial assistance. Minnesota nonprofit hospitals are required under state law to offer financial assistance programs. If you receive your infusion at a nonprofit hospital system like Allina, Fairview, or CentraCare, ask about charity care or sliding-scale payment before your appointment.

Site-of-care optimization. Receiving your infusion at a freestanding infusion center rather than a hospital outpatient department can reduce facility fees by 30% to 50%. A 2021 analysis in Health Affairs found that site-of-care shifts for injectable osteoporosis drugs saved payers an average of $440 per infusion episode [12].

Timing your infusion strategically. If you have a high-deductible plan, scheduling your zoledronic acid infusion after a planned surgery or other large medical expense in the same plan year means you may have already met your deductible, reducing your share to coinsurance only.

Telehealth Prescribing for Zoledronic Acid in Minnesota

Minnesota permits telehealth prescribing of zoledronic acid. A clinician can evaluate your bone density results, review your fracture risk using the FRAX calculator, and write the prescription during a virtual visit. The infusion itself must be administered in person at a licensed facility.

The Minnesota Telehealth Act, updated in 2023, requires private insurers to cover telehealth visits at parity with in-person visits [13]. This means your telehealth consultation for osteoporosis management should be covered at the same rate as an office visit. Medicare also covers telehealth osteoporosis consultations for Minnesota beneficiaries following the permanent flexibilities adopted after the COVID-19 public health emergency.

Telehealth is particularly useful for patients in greater Minnesota, where endocrinology and rheumatology specialists may be hours away. A DXA scan can be performed at a local imaging center, results forwarded to a specialist via telehealth, and the infusion arranged at the nearest qualified facility.

Clinical Evidence Supporting Zoledronic Acid for Osteoporosis

The HORIZON Key Fracture Trial (HORIZON-PFT) established zoledronic acid as a first-line treatment for postmenopausal osteoporosis. This randomized, double-blind, placebo-controlled trial enrolled 7,765 postmenopausal women with osteoporosis and followed them for 3 years. Zoledronic acid 5 mg given once yearly reduced the risk of morphometric vertebral fractures by 70% (RR 0.30 to 95% CI 0.24 to 0.38) and hip fractures by 41% (RR 0.59 to 95% CI 0.42 to 0.83) compared with placebo [1].

A companion trial, HORIZON-RFT, studied zoledronic acid in 2,127 patients who had sustained a recent hip fracture. Annual zoledronic acid reduced the rate of new clinical fractures by 35% (HR 0.65 to 95% CI 0.50 to 0.84) and all-cause mortality by 28% (HR 0.72 to 95% CI 0.56 to 0.93) [14]. The mortality reduction was an unexpected finding and remains one of the strongest mortality signals for any osteoporosis treatment.

"Once-yearly intravenous zoledronic acid significantly reduced the risk of vertebral, hip, and other fractures," the HORIZON-PFT investigators wrote in the New England Journal of Medicine [1]. This level of fracture reduction, combined with the convenience of annual dosing, makes zoledronic acid especially appealing for patients who struggle with the weekly or monthly oral bisphosphonate regimen.

The Endocrine Society's 2019 clinical practice guideline recommends zoledronic acid as a first-line pharmacologic option for postmenopausal women at high fracture risk, alongside oral alendronate, oral risedronate, and denosumab [15]. For patients at very high fracture risk (recent vertebral fracture, T-score below -3.0, or high FRAX probability), the guideline suggests considering anabolic agents like teriparatide or romosozumab before transitioning to zoledronic acid for maintenance.

Side Effects and What Minnesota Patients Should Know Before Infusion

The most common side effect of zoledronic acid is an acute-phase reaction occurring within 1 to 3 days after the first infusion. Symptoms include fever, myalgia, arthralgia, and headache, affecting roughly 30% to 35% of patients after the first dose [1]. These symptoms are typically mild to moderate and resolve within 72 hours. Acetaminophen or ibuprofen taken before and after the infusion can reduce severity. The acute-phase reaction rate drops to under 10% with subsequent annual infusions.

Kidney function must be assessed before each infusion. Zoledronic acid is contraindicated in patients with creatinine clearance <35 mL/min [3]. The infusion must be delivered over no fewer than 15 minutes to minimize renal risk. Adequate hydration before and after the infusion is standard protocol.

Rare but serious adverse events include osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). In the HORIZON-PFT extension study, ONJ occurred in 1 out of 3,862 patients receiving zoledronic acid over 6 years, and no atypical femoral fractures were confirmed [16]. These risks are dose- and duration-dependent and are far more common with the higher-dose, more frequent zoledronic acid regimen used in oncology (4 mg every 3 to 4 weeks) than with the osteoporosis dose (5 mg once yearly).

Minnesota infusion centers typically schedule a 30- to 45-minute appointment window for the infusion itself plus a brief post-infusion monitoring period. Bring a current serum creatinine result (drawn within 30 days) and confirm your calcium and vitamin D status with your prescriber beforehand.